Manchester Royal Eye Hospital, Manchester Academic Health Science Centre, Manchester, UK.
Faculty of Medical and Human Sciences, Centre for Ophthalmology and Vision Sciences, Institute of Human Development, University of Manchester, Manchester, UK.
Acta Ophthalmol. 2018 Aug;96(5):494-498. doi: 10.1111/aos.13627. Epub 2017 Dec 14.
To determine whether the ocular phenotype in patients with mucopolysaccharidosis type I (MPSI) Hurler is affected by the efficacy of previous haemopoietic stem cell transplantation (HSCT).
A retrospective cohort study of patients with MPSI who had undergone treatment with HSCT.
Ocular phenotype was documented for each patient and compared to levels of biomarkers representing efficacy of previous transplantation.
Assessment of visual acuity (VA), severity of corneal clouding and the presence of optic neuropathy or retinopathy. Biomarker assessment included dermatan sulphate/chondroitin sulphate (DS/CS) ratio and iduronidase enzyme level.
Severe corneal clouding was significantly greater in patients with lower iduronidase levels (p = 0.023) and raised DS/CS ratio (R = 0.28 p = 0.043). Better VA was related to a higher iduronidase levels (R = 0.15, p = 0.004) and lower DS/CS ratio (R = 0.38, p = 0.001).
Improved ocular phenotypes in MPSI are associated with markers signifying efficacy of prior transplant. Early and effective HSCT may result in a better visual prognosis and reduction in ocular complications for patients with MPSI.
确定黏多糖贮积症 I 型(MPSI)Hurler 患者的眼部表型是否受先前造血干细胞移植(HSCT)疗效的影响。
对接受过 HSCT 治疗的 MPSI 患者进行的回顾性队列研究。
记录每位患者的眼部表型,并将其与代表先前移植疗效的生物标志物水平进行比较。
评估视力(VA)、角膜混浊程度以及视神经病变或视网膜病变的存在。生物标志物评估包括硫酸皮肤素/硫酸软骨素(DS/CS)比值和艾杜糖醛酸酶水平。
较低的艾杜糖醛酸酶水平(p=0.023)和升高的 DS/CS 比值(R=0.28,p=0.043)与更严重的角膜混浊显著相关。更好的 VA 与更高的艾杜糖醛酸酶水平(R=0.15,p=0.004)和更低的 DS/CS 比值(R=0.38,p=0.001)相关。
MPSI 中眼部表型的改善与表明先前移植疗效的标志物相关。早期和有效的 HSCT 可能为 MPSI 患者带来更好的视觉预后,并减少眼部并发症。